<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867135</url>
  </required_header>
  <id_info>
    <org_study_id>190325002</org_study_id>
    <nct_id>NCT04867135</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Amikacin in Neonates</brief_title>
  <official_title>Population Pharmacokinetics of Amikacin in Suspected Cases of Neonatal Sepsis: Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aminoglycosides such as Amikacin are routinely used in newborns for the treatment of neonatal&#xD;
      sepsis due to gram-negative bacilli. Despite the frequency of this indication, it has not yet&#xD;
      been possible to establish definitive dosage schedules that ensure effectiveness and low risk&#xD;
      of toxicity, due to the high pharmacokinetic variability observed in this population.&#xD;
&#xD;
      In addition to anthropometric variables, evidence from retrospective studies suggests that&#xD;
      sepsis could be capable of significantly modifying the pharmacokinetics of aminoglycosides in&#xD;
      neonates, but they suggest conducting prospective studies of higher methodological quality to&#xD;
      verify this hypothesis.&#xD;
&#xD;
      Due to the lack of pharmacokinetic and pharmacodynamic (PK / PD) studies of Amikacin in this&#xD;
      group of patients, we have raised the need to develop a prospective observational study;&#xD;
      describing a PK / PD model of amikacin in newborns with suspected sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three blood samples will be taken from each of the 138 patients. As a standard of care, a&#xD;
      sample will always be taken at 0.5h (Cmax) after the first dose and a sample before the&#xD;
      second dose, which can be at 24h, 36h, or 48h as per physician indication. The third sample&#xD;
      will be collected according to what has been assigned by a block randomization method, in one&#xD;
      of the following moments: 1, 2, 4, 8, 12 or 18 hours after the administration of the first&#xD;
      dose of Amikacin.&#xD;
&#xD;
      The methods used to analyze the samples will be: Particle Enhanced Turbidimetric Immunoassay&#xD;
      (PETIA), Architect C8000; and Homogeneous Microparticle Immunoassay in Solution (KIMS), Roche&#xD;
      systems. The determination of the susceptibility and minimum Inhibitory Concentration (MIC)&#xD;
      will be carried out by the laboratories of each hospital by agar dilution method.&#xD;
&#xD;
      PK/PD profile of amikacin will be evaluated with NONMEM (non-linear mixed effects modelling)&#xD;
      software for the analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of Distribution (L/Kg) of Amikacin</measure>
    <time_frame>first dose amikacin (1 day)</time_frame>
    <description>The mean population parameter and their interindividual variability in neonates with suspected sepsis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (L/h) of Amikacin</measure>
    <time_frame>first dose amikacin (1 day)</time_frame>
    <description>The mean population parameter and their interindividual variability in neonates with suspected sepsis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK/PD targets of amikacin</measure>
    <time_frame>first dose amikacin (1 day)</time_frame>
    <description>Peak Plasma Concentration (Cmax) over 8 fold Minimum Inhibitory Concentration (MIC) or Cmax: 24-35 mg/L</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Neonatal Sepsis, Late-Onset</condition>
  <arm_group>
    <arm_group_label>No Sepsis / Sepsis</arm_group_label>
    <description>To compare amikacin PK / PD models of newborns with a confirmed diagnosis of sepsis (clinical or microbiological) and with ruled out sepsis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin Sulfate Injection</intervention_name>
    <description>The dose and frequency of amikacin was defined by each hospital.</description>
    <arm_group_label>No Sepsis / Sepsis</arm_group_label>
    <other_name>Amikacin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to neonatal intensive care units of two hospitals of high-complexity in&#xD;
        Chile&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receive at least one dose of Amikacin&#xD;
&#xD;
          -  Be at least three days old (72 hours)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receive the first dose of Amikacin in a healthcare center other than those included in&#xD;
             the research&#xD;
&#xD;
          -  Patient on renal replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nicolas F Severino, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facultad de Medicina. Pontificia Universidad Católica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas F Severino, PharmD</last_name>
    <phone>+56223453193</phone>
    <email>nseverin@med.puc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Soledad Urzúa, MD</last_name>
    <phone>+56223453224</phone>
    <email>soleurzua@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico UC-Christus</name>
      <address>
        <city>Santiago</city>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas F Severino, PharmD</last_name>
      <phone>+56223543193</phone>
      <email>nseverin@med.puc.cl</email>
    </contact>
    <contact_backup>
      <last_name>Maria Soledad Urzúa, MD</last_name>
      <phone>+56223543224</phone>
      <email>soleurzua@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol. 2005 Jan;59(1):54-61.</citation>
    <PMID>15606440</PMID>
  </reference>
  <reference>
    <citation>Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2009 Jul;65(7):705-13. doi: 10.1007/s00228-009-0637-4. Epub 2009 Mar 21.</citation>
    <PMID>19305985</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal Sepsis</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Population Pharmacokinetic</keyword>
  <keyword>Neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

